Evidence map›Paper›PMID 29069766›Full record

ArticleOncotarget2017

Prognostic significance of clinicopathological factors in early breast cancer: 20 years of follow-up in a single-center analysis.

Valentina Cocciolone, Katia Cannita, Maria Letizia Calandrella, Enrico Ricevuto, Paola Lanfiuti Baldi, Tina Sidoni, Azzurra Irelli, Stefania Paradisi, Laura Pizzorno, Valter Resta and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Valentina CoccioloneMedical Oncology, S. Salvatore Hospital, University of L'Aquila, Via Vetoio, 67100 L'Aquila, Italy.
Katia CannitaMedical Oncology, S. Salvatore Hospital, University of L'Aquila, Via Vetoio, 67100 L'Aquila, Italy.
Maria Letizia CalandrellaMedical Oncology, S. Salvatore Hospital, University of L'Aquila, Via Vetoio, 67100 L'Aquila, Italy.
Enrico RicevutoDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio, 67100 L'Aquila, Italy.
Paola Lanfiuti BaldiMedical Oncology, S. Salvatore Hospital, University of L'Aquila, Via Vetoio, 67100 L'Aquila, Italy.
Tina SidoniMedical Oncology, S. Salvatore Hospital, University of L'Aquila, Via Vetoio, 67100 L'Aquila, Italy.
Azzurra IrelliMedical Oncology, S. Salvatore Hospital, University of L'Aquila, Via Vetoio, 67100 L'Aquila, Italy.
Stefania ParadisiMedical Oncology, S. Salvatore Hospital, University of L'Aquila, Via Vetoio, 67100 L'Aquila, Italy.
Laura PizzornoBreast Unit, S. Salvatore Hospital, L'Aquila, Via Vetoio, 67100 L'Aquila, Italy.
Valter RestaBreast Unit, S. Salvatore Hospital, L'Aquila, Via Vetoio, 67100 L'Aquila, Italy.
Alberto BafileBreast Unit, S. Salvatore Hospital, L'Aquila, Via Vetoio, 67100 L'Aquila, Italy.
Edoardo AlesseDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio, 67100 L'Aquila, Italy.
Alessandra TessitoreDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio, 67100 L'Aquila, Italy.
Corrado FicorellaMedical Oncology, S. Salvatore Hospital, University of L'Aquila, Via Vetoio, 67100 L'Aquila, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo quantify the effect of traditional prognostic factors [nodal status, estrogen-receptor (ER), progesterone-receptor (PR), human epidermal growth factor receptor 2 (HER2)] on long-term outcome of patients with early breast cancer (EBC), treated in clinical practice over a period of about twenty years.

results1198 consecutive patients were identified. Median DFS (disease-free survival): ER+/PR±/HER2-, 165 months (mo) if node-negative (N0) and 114mo if node-positive (N+) ( MATERIALS AND

methodsDisease-free survival (DFS) and overall survival (OS) were evaluated according to tumor characteristics, based on information retrospectively retrieved from patients' medical records.

conclusionsPathological tumor characteristics and nodal status still represent useful tools in treatment selection and follow-up decision making of EBC patients in clinical practice.

Indexed as

20-year follow-upclinical practiceclinicopathological prognostic factorsearly breast cancersurvival

Identifiers

PMID29069766
PMCPMC5641109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.